Low INR to Minimize Bleeding with Mechanical Valves Trial

Last updated: March 4, 2025
Sponsor: Population Health Research Institute
Overall Status: Active - Recruiting

Phase

3

Condition

Thromboembolism

Hemorrhage

Treatment

Warfarin

Clinical Study ID

NCT03636295
5139
  • Ages > 18
  • All Genders

Study Summary

This study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical bileaflet heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot formation and stroke. These results have the potential to reduce the burden of bleeding in patients with a mechanical heart valve who require lifelong warfarin (Coumadin) treatment.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Age is 18 or older at the time of enrolment

  • Have had a bileaflet mechanical heart valve implant in the aortic position 3 or moremonths ago

  • Written informed consent from either the patient or substitute decision maker

Exclusion

Exclusion criteria:

  • Has a second implanted mechanical valve (any position)

  • Lower boundary of planned INR range is less than 2.0

  • Pregnant or expecting to become pregnant during the study follow-up

Study Design

Total Participants: 2625
Treatment Group(s): 1
Primary Treatment: Warfarin
Phase: 3
Study Start date:
September 05, 2019
Estimated Completion Date:
December 31, 2026

Study Description

Warfarin (Coumadin) is a blood thinner used to prevent blood clot formation in patients with mechanical heart valves. Blood clots can block blood flow to the brain, heart, or other parts of the body. Mechanical heart valves increases the risk of clot so patients with a mechanical heart valve must take warfarin to reduce their risk of stroke and other blood clot-related problems.

The degree to which warfarin 'works' varies from person to person, and so dosage is determined by measuring each person's response to the drug as an 'international normalized ratio' or INR. A patient with an INR over 1.0 has blood that takes longer to clot than average, and increasing INR values represent increasing time required for blood to clot. While an INR over 1.0 decreases clotting risk, it also increases bleeding risk. It is important to carefully balance these risks.

Specific INR targets have been recommended for patients with a mechanical heart valve, but these recommendations differ between scientific groups and are based on low quality evidence. Recent studies suggest that a lower INR target range than is currently recommended can be used safely. A laboratory study showed that warfarin effectively prevents blood clot formation on mechanical heart valves as long as the INR is 1.5 or above. Two moderately-sized clinical studies showed that an INR target range of 1.5-2.5 resulted in less bleeding than the usual higher target range without increasing blood clot formation or stroke in patients with a newer valve model. Whether we could use a lower INR target range for patients with a mechanical aortic valve remains controversial.

This study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical bileaflet heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot formation and stroke. These results have the potential to reduce the burden of bleeding in patients with a mechanical heart valve who require lifelong warfarin (Coumadin) treatment.

Connect with a study center

  • Ziekenhuis Oost-Limburg

    Genk, Limburg 3600
    Belgium

    Active - Recruiting

  • Universitair Ziekenhuis Leuven

    Leuven, 3000
    Belgium

    Active - Recruiting

  • Sociedade Hospitalar Angelina Caron

    Campina Grande Do Sul, Parana 83430-000
    Brazil

    Active - Recruiting

  • HEW Cardiologia LTDA

    Joinville, Santa Catarina 89204-250
    Brazil

    Active - Recruiting

  • InCor-HCFMUSP

    Cerqueira César, São Paulo 05403-000
    Brazil

    Active - Recruiting

  • Fundação Universitária de Cardiologia mantededora do Instituto de Cardiologia e Transplantes do Distrito Federal

    Brasilia,
    Brazil

    Active - Recruiting

  • Dante Pazzanese Institute of Cardiology

    Sao Paulo,
    Brazil

    Active - Recruiting

  • Nova Scotia Health Authority

    Halifax, Nova Scotia B3S 0H6
    Canada

    Site Not Available

  • Hamilton General Hospital

    Hamilton, Ontario L8L 2X2
    Canada

    Active - Recruiting

  • London Health Sciences Centre Research Inc.

    London, Ontario N6C 2R5
    Canada

    Active - Recruiting

  • The Ottawa Hospital Research Institute

    Ottawa, Ontario K1H 8L6
    Canada

    Active - Recruiting

  • Centre hospitalier de l'Université de Montréal

    Montreal, Quebec H2X 3E4
    Canada

    Site Not Available

  • Jewish General Hospital

    Montréal, Quebec H3T 1E2
    Canada

    Active - Recruiting

  • Fuwai Hospital, CAMS & PUMC

    Beijing,
    China

    Active - Recruiting

  • Soonchunhyang University Gumi Hospital

    Gumi,
    Korea, Republic of

    Active - Recruiting

  • Erasmus University Medical Centre

    Rotterdam, 3015
    Netherlands

    Active - Recruiting

  • Meshalkin National Medical Research Center

    Novosibirsk,
    Russian Federation

    Active - Recruiting

  • King Faisal Specialist Hospital & Research Centre

    Riyadh,
    Saudi Arabia

    Active - Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08025
    Spain

    Active - Recruiting

  • South Tees Hospitals NHS Foundation Trust of The James Cook University Hospital

    Middlesbrough,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.